

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JD Health International Inc.

京东健康股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Codes: 6618 (HKD counter) and 86618 (RMB counter))

INSIDE INFORMATION

UNAUDITED UPDATE ON THE 2023 THIRD QUARTER

This announcement is issued by JD Health International Inc. (the “**Company**” or “**JD Health**”, and together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Business Update

- During the third quarter of 2023, JD Health launched various initiatives and brand strategies, further enhancing consumers’ trust and recognition in and reliance on JD Health for online healthcare services and pharmaceutical products. We maintained fast user growth and the annual active user accounts for the 12 months ended September 30, 2023 increased to 175 million.
- During the third quarter of 2023, JD Health joined hands with pharmaceutical companies to debut a variety of new specialty drugs online, including SOLIQUA[®] (Insulin Glargine and Lixisenatide Injection), an innovative medicine for diabetes, and OLUMIANT[®] (Baricitinib Tablets), an innovative targeted drug. These collaborations bolstered our ongoing efforts to improve access to quality-assured pharmaceuticals while providing patients with a better purchasing experience. In addition, JD Health has strengthened its strategic partnerships with a number of pharmaceutical companies, including LEO Pharma, DYNE Pharma and Dong-E-E-Jiao, to consistently enhance the “Retail pharmacy + Healthcare services” one-stop experience.
- In July 2023, JD Health Polyclinic Center officially commenced operations in Yizhuang, Beijing. Leveraging JD Health’s digital capabilities, the physical examination center seamlessly integrates online and offline services and offers users with a completely paperless experience. After examinations, users can easily access to an array of online medical and healthcare services, including examination results interpretation, follow-up consultations and other professional medical advice. Going forward, JD Health will continue to build out its healthcare service offerings, striving to provide consumers with a more comprehensive and integrated “online + offline” medical and healthcare services.
- In July 2023, JD Health officially introduced its “Jingyi Qianxun” large language model (LLM) for medical and healthcare applications, which can be applied to diverse scenarios, enabling AI-driven advancements across service offerings and solutions. Our healthcare LLM served as the cornerstone of JD Health’s technology, and will continue to empower the innovation of online medical and healthcare services.

Unaudited Financial Information

The Company is pleased to announce the unaudited revenue and operating income of the Group for the three months ended September 30, 2023 together with comparative figures for the corresponding period of 2022:

	Three months ended September 30,		
	2023	2022	Change
	<i>RMB'000</i>	<i>RMB'000</i>	(%)
	(Unaudited)	(Unaudited)	
Revenue	11,585,424	10,519,625	10.1
Operating income*	174,606	77,225	126.1
Non-IFRS operating income**	744,854	654,564	13.8

* Operating income consists of gross profit deducting fulfillment expenses, selling and marketing expenses, research and development expenses, general and administrative expenses, and impairment losses under expected credit loss model, net of reversal.

** We define “non-IFRS operating income” as operating income for the period, excluding share-based payment expenses for the period. We exclude this item because it is non-operating in nature, not indicative of our core operating results and business outlook, and it does not generate any cash outflows.

The above information is based on the board (the “**Board**”) of directors (the “**Directors**”) of the Company’s preliminary review of the internal data currently available and gathered by the Company only and is not intended to be a comprehensive statement of the Group’s financial result. The said information and data have not been audited or reviewed by the Company’s auditors and may be subject to change and adjustment.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JD Health International Inc.
Mr. Enlin Jin
Executive Director

Hong Kong, November 15, 2023

As of the date of this announcement, the Board comprises Mr. Enlin Jin as the executive Director, Mr. Richard Qiangdong Liu and Mr. Qingqing Yi as non-executive Directors, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen and Mr. Ying Wu as independent non-executive Directors.